§ 02 — Comparison

Compare regulatory pathways side-by-side

Benchmark MAHMAH, GMPGMP, HTAHTA and pathway requirements across up to three markets.

Country A

Country B

Country C

Highlight differences

Criterion	🇿🇦South Africa	🇺🇸United States
Authority & dossier
Regulatory authority	SAHPRA	FDA
English submissions	Yes	Yes
CTD accepted	Yes	Yes
eCTD accepted	Yes	Yes
Reliance pathway	Available	None
Reference agencies	FDA, EMA (centralised), MHRA, Health Canada +2	—
Lead pathway (timeline & fees) — Standard Registration (Full Review) · New Drug Application — 505(b)(1)
Pathway name	Standard Registration (Full Review)	New Drug Application — 505(b)(1)
Approval timeline	365–1095 days	304–365 days
Application fee	ZAR 38,000	USD 4,310,002
Annual renewal	ZAR 16,500	USD 416,734
Local representative	Required	Not required
Local manufacturing	Not required	Not required
GMP inspection	Required	Required
MAH & local presence
Local entity required	Yes	No
Local responsible person	Yes	Yes
RP role	A SA-resident Responsible Pharmacist registered with the South African Pharmacy Council (SAPC) is mandatory for the Section 22C licence. A separate Pharmacovigilance Officer is required and must report to SAHPRA Pharmacovigilance.	US Agent: a person residing or maintaining a place of business in the US, designated to act on behalf of the foreign establishment for FDA communications, including notification of inspections.
Accelerated pathways
Designations available	4 designations	6 designations
Examples	Risk-Based Prioritised Review, WHO Collaborative Procedure, Section 21 Authorisation (Pre-Approval Access) +1	Priority Review, Breakthrough Therapy Designation, Accelerated Approval — Subpart H/E +3
Post-approval lifecycle
Variations framework	Post-approval variations classified into Type IA, IB, II, and Notification, broadly aligned with EU framework. SAHPRA variations guideline (2020) implemented after MCC-to-SAHPRA transition.	FDA classifies post-approval changes as: Annual Reportable, Changes Being Effected (CBE-0 immediate, CBE-30 with 30-day pre-implementation notice), and Prior Approval Supplements (PAS) — the most significant changes requiring FDA approval before implementation. Major manufacturing or labelling changes typically require a PAS.
Renewal cycle	Marketing authorisations valid for 5 years; renewal required 6 months before expiry. Renewal includes updated PSUR, sales/distribution data, and pharmacovigilance summary.	FDA does not require periodic renewal of NDAs or BLAs — approvals remain in effect indefinitely subject to compliance, payment of annual program fees, and post-marketing requirements. Annual reports are required.
Pharmacovigilance	SAHPRA Pharmacovigilance Department coordinates with the National Adverse Drug Event Monitoring Centre (NADEMC) at University of Cape Town. PSURs aligned with ICH E2C(R2). Mandatory ICSR reporting via SAHPRA Med Safety app and online portal. South Africa is a WHO-UMC member.	Mandatory expedited reporting of serious unexpected ADRs within 15 calendar days; periodic safety reports (PADERs/PAERs) for the first 3 years post-approval, then annually. PSURs in ICH E2C(R2) format accepted in lieu of PADERs by agreement. FAERS database receives spontaneous reports. Post-Marketing Requirements (PMRs) and Commitments (PMCs) tracked publicly.
Unlicensed access
Named Patient Supply	Available	Available
Compassionate Use	Available	Available
Emergency Import	Available	Available
Parallel Import	Not permitted	Not permitted
Clinical trials
CTA approval	Required	Required
Ethics approval	Yes	Yes
CTA timeline	60–180 days	30–30 days
GCP standard	South African GCP Guidelines + ICH-GCP	ICH E6(R3) (adopted via FDA guidance January 2025); 21 CFR 312, 314, 50, 56
Pricing & reimbursement
Price regulation	Regulated	Free pricing
Reference pricing	Yes	No
HTA required	No	No
HTA body	National Essential Medicines List Committee (NEMLC); NHI HTA committee under development	ICER (Institute for Clinical and Economic Review) — independent, non-binding

Verdict colours indicate lower, moderate, or higher regulatory burden — they're not value judgements on a market.

Authority & dossier

Regulatory authority

South AfricaSAHPRA
United StatesFDA

English submissions

South AfricaYes
United StatesYes

CTD accepted

South AfricaYes
United StatesYes

eCTD accepted

South AfricaYes
United StatesYes

Reliance pathway

South AfricaAvailable
United StatesNone

Reference agencies

South AfricaFDA, EMA (centralised), MHRA, Health Canada +2
United States—

Lead pathway (timeline & fees) — Standard Registration (Full Review) · New Drug Application — 505(b)(1)

Pathway name

South AfricaStandard Registration (Full Review)
United StatesNew Drug Application — 505(b)(1)

Approval timeline

South Africa365–1095 days
United States304–365 days

Application fee

South AfricaZAR 38,000
United StatesUSD 4,310,002

Annual renewal

South AfricaZAR 16,500
United StatesUSD 416,734

Local representative

South AfricaRequired
United StatesNot required

Local manufacturing

South AfricaNot required
United StatesNot required

GMP inspection

South AfricaRequired
United StatesRequired

MAH & local presence

Local entity required

South AfricaYes
United StatesNo

Local responsible person

South AfricaYes
United StatesYes

RP role

South AfricaA SA-resident Responsible Pharmacist registered with the South African Pharmacy Council (SAPC) is mandatory for the Section 22C licence. A separate Pharmacovigilance Officer is required and must report to SAHPRA Pharmacovigilance.
United StatesUS Agent: a person residing or maintaining a place of business in the US, designated to act on behalf of the foreign establishment for FDA communications, including notification of inspections.

Accelerated pathways

Designations available

South Africa4 designations
United States6 designations

Examples

South AfricaRisk-Based Prioritised Review, WHO Collaborative Procedure, Section 21 Authorisation (Pre-Approval Access) +1
United StatesPriority Review, Breakthrough Therapy Designation, Accelerated Approval — Subpart H/E +3

Post-approval lifecycle

Variations framework

South AfricaPost-approval variations classified into Type IA, IB, II, and Notification, broadly aligned with EU framework. SAHPRA variations guideline (2020) implemented after MCC-to-SAHPRA transition.
United StatesFDA classifies post-approval changes as: Annual Reportable, Changes Being Effected (CBE-0 immediate, CBE-30 with 30-day pre-implementation notice), and Prior Approval Supplements (PAS) — the most significant changes requiring FDA approval before implementation. Major manufacturing or labelling changes typically require a PAS.

Renewal cycle

South AfricaMarketing authorisations valid for 5 years; renewal required 6 months before expiry. Renewal includes updated PSUR, sales/distribution data, and pharmacovigilance summary.
United StatesFDA does not require periodic renewal of NDAs or BLAs — approvals remain in effect indefinitely subject to compliance, payment of annual program fees, and post-marketing requirements. Annual reports are required.

Pharmacovigilance

South AfricaSAHPRA Pharmacovigilance Department coordinates with the National Adverse Drug Event Monitoring Centre (NADEMC) at University of Cape Town. PSURs aligned with ICH E2C(R2). Mandatory ICSR reporting via SAHPRA Med Safety app and online portal. South Africa is a WHO-UMC member.
United StatesMandatory expedited reporting of serious unexpected ADRs within 15 calendar days; periodic safety reports (PADERs/PAERs) for the first 3 years post-approval, then annually. PSURs in ICH E2C(R2) format accepted in lieu of PADERs by agreement. FAERS database receives spontaneous reports. Post-Marketing Requirements (PMRs) and Commitments (PMCs) tracked publicly.

Unlicensed access

Named Patient Supply

South AfricaAvailable
United StatesAvailable

Compassionate Use

South AfricaAvailable
United StatesAvailable

Emergency Import

South AfricaAvailable
United StatesAvailable

Parallel Import

South AfricaNot permitted
United StatesNot permitted

Clinical trials

CTA approval

South AfricaRequired
United StatesRequired

Ethics approval

South AfricaYes
United StatesYes

CTA timeline

South Africa60–180 days
United States30–30 days

GCP standard

South AfricaSouth African GCP Guidelines + ICH-GCP
United StatesICH E6(R3) (adopted via FDA guidance January 2025); 21 CFR 312, 314, 50, 56

Pricing & reimbursement

Price regulation

South AfricaRegulated
United StatesFree pricing

Reference pricing

South AfricaYes
United StatesNo

HTA required

South AfricaNo
United StatesNo

HTA body

South AfricaNational Essential Medicines List Committee (NEMLC); NHI HTA committee under development
United StatesICER (Institute for Clinical and Economic Review) — independent, non-binding